These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease. Caenazzo A; Pietrogrande F; Polato G; Piva E; Masiero M; Sgarabotto D; Girolami A Acta Haematol; 1989; 81(3):131-5. PubMed ID: 2496560 [TBL] [Abstract][Full Text] [Related]
5. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity. Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837 [TBL] [Abstract][Full Text] [Related]
6. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation]. Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211 [TBL] [Abstract][Full Text] [Related]
7. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes]. Hernández JM; San Miguel JF; González M; Moraleda JM; Moro MJ; Hernández J; Cuesta B; López Borrasca A Med Clin (Barc); 1991 Sep; 97(10):369-72. PubMed ID: 1745085 [TBL] [Abstract][Full Text] [Related]
8. Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3. Kobayashi S; Teramura M; Hoshino S; Motoji T; Oshimi K; Mizoguchi H Br J Haematol; 1993 Apr; 83(4):539-44. PubMed ID: 7686030 [TBL] [Abstract][Full Text] [Related]
15. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders. Gersuk GM; Carmel R; Pattengale PK Blood; 1989 Nov; 74(7):2330-4. PubMed ID: 2804368 [TBL] [Abstract][Full Text] [Related]
16. Differential effects of TGF-beta 1 on normal and leukemic human hematopoietic cell proliferation. Murohashi I; Endho K; Nishida S; Yoshida S; Jinnai I; Bessho M; Hirashima K Exp Hematol; 1995 Aug; 23(9):970-7. PubMed ID: 7543418 [TBL] [Abstract][Full Text] [Related]
17. The effect of cyclosporin A used alone and in combination with either 2-chlorodeoxyadenosine or fludarabine on normal and chronic myelogenous leukemia progenitors in vitro. Korycka A; Robak T Arch Immunol Ther Exp (Warsz); 2003; 51(1):61-7. PubMed ID: 12691305 [TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia. Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157 [TBL] [Abstract][Full Text] [Related]
19. Spontaneous megakaryocytic colony formation does not discriminate between essential thrombocythemia and polycythemia vera. Escoffre-Barbe M; Amiot L; Beaucournu P; Jego P; Grulois I; Grosbois B; Bernard M; Fest T; Lamy T; Fardel O Am J Hematol; 2006 Jul; 81(7):554-6. PubMed ID: 16755572 [TBL] [Abstract][Full Text] [Related]
20. Stimulation of normal rat bone marrow fibroblast proliferation by sera from leukemic Fischer rats. Bauldry SA; Wilson FD; Stromberg PC; Ackerman GA Exp Hematol; 1985 Sep; 13(8):750-9. PubMed ID: 4043259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]